Previous studies have suggested that CRC exosomes can promote cetuximab resistance in an apparently AREG‐independent fashion via the PTEN/Akt pathway, another target pathway of EGFR (Zhang et al., 2017), or via the transfer of the long non‐coding RNA uroepithelial carcinoma‐associated‐1 (UCA‐1) (Yang et al., 2018). The gene discussed is EGFR; the disease is colorectal carcinoma.